390 related articles for article (PubMed ID: 33740521)
1. A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling.
Chang TY; Nepali K; Chen YY; Yang YSH; Hsu KC; Yen Y; Pan SL; Liou JP; Lee SB
Biomed Pharmacother; 2021 Jun; 138():111485. PubMed ID: 33740521
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Hoffmann MJ; Meneceur S; Hommel K; Schulz WA; Niegisch G
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33670166
[TBL] [Abstract][Full Text] [Related]
4. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
Cheng C; Yun F; Ullah S; Yuan Q
Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
[TBL] [Abstract][Full Text] [Related]
6. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
8. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
9. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
Liu Y; Tong Y; Yang X; Li F; Zheng L; Liu W; Wu J; Ou R; Zhang G; Hu M; Liu Z; Lu L
Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146
[TBL] [Abstract][Full Text] [Related]
10. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
12. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
Nepali K; Chang TY; Lai MJ; Hsu KC; Yen Y; Lin TE; Lee SB; Liou JP
Eur J Med Chem; 2020 Jun; 196():112291. PubMed ID: 32325365
[TBL] [Abstract][Full Text] [Related]
13. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
Singh A; Chang TY; Kaur N; Hsu KC; Yen Y; Lin TE; Lai MJ; Lee SB; Liou JP
Eur J Med Chem; 2021 Apr; 215():113169. PubMed ID: 33588178
[TBL] [Abstract][Full Text] [Related]
14. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
15. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
[TBL] [Abstract][Full Text] [Related]
16. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Schech A; Kazi A; Yu S; Shah P; Sabnis G
Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
Feng J; Fang H; Wang X; Jia Y; Zhang L; Jiao J; Zhang J; Gu L; Xu W
Cancer Biol Ther; 2011 Mar; 11(5):477-89. PubMed ID: 21263218
[TBL] [Abstract][Full Text] [Related]
20. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.
Kalin JH; Wu M; Gomez AV; Song Y; Das J; Hayward D; Adejola N; Wu M; Panova I; Chung HJ; Kim E; Roberts HJ; Roberts JM; Prusevich P; Jeliazkov JR; Roy Burman SS; Fairall L; Milano C; Eroglu A; Proby CM; Dinkova-Kostova AT; Hancock WW; Gray JJ; Bradner JE; Valente S; Mai A; Anders NM; Rudek MA; Hu Y; Ryu B; Schwabe JWR; Mattevi A; Alani RM; Cole PA
Nat Commun; 2018 Jan; 9(1):53. PubMed ID: 29302039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
